Welcome to Avirmax Inc.
Avirmax, Inc. based in San Francisco Bay Area, is dedicated to the innovation, development, and manufacture of adeno-associated virus (AAV) vector mediated biotherapeutics using its proprietary protein therapeutics and Bac-to-AAV technologies. Avirmax’s AAV Innovation Platform, a robust streamlined assembly line of novel AAV vector discovery and development, enables us to become a powerhouse of rAAV therapeutics due to its highly transducible AAV vectors with high titers at production and enhanced expression of gene of interest (GOI) in target cells. Our ultimate goal is to deliver patients with effective, safe, long-acting AAV-mediated biotherapeutics in the most affordable and accessible manner possible.
AAV Capsid Engineering
Enhanced GOI Expression
Generic rAAV Manufacturing Technologies
Avirmax Services cover a full range of offerings from molecular cloning, transgene optimization, process development through early to late-stage, clinical manufacturing, viral vector testing and regulatory submission documents.
We have the best Services
Avirmax is at preclinical stage of biotherapeutics development using rAAV delivery system. Currently, it is developing multiple candidates lead rAAV vectors. The following listed in the table are examples of its product pipelines.